ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1026

Corticosteroids Improves Renal Survival in Chinese Patients with Early-Stage IgA Nephropathy

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Pei, Gaiqin, Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China., Chengdu, China
  • Tang, Yi, West China Hospital of Sichuan University, Chengdu, China
  • Qin, Wei, West China Hospital of Sichuan University, Chengdu, China

The therapy for immunoglobulin A nephropathy(IgAN) patients remains controversial. This study aims to evaluate the effects of corticosteroids and immunosuppressive therapy in Chinese early stage IgAN patients with estimated glomerular filtration rate(eGFR) ≥45mL/min/1.73 m2 and mean proteinuria≥1g/24h.


Patients with biopsy proven IgAN were retrospectively enrolled from 2007 to 2016.Patients were categorized into supportive care (SC),steroids alone(CS),and steroids plus immunosuppressant(IT) groups.Responses to therapy included complete remission(CR), partial remission(PR),no response(NR)and end stage renal disease(ESRD).The renal outcome was defined as a 50% decline in eGFR and/or ESRD.


715 patients(Male 47% and Female 53%)were recruited and followed for a mean of 44.69±24.13 months. The rate of CR was 81.8%, 62.7%, 37% in CS, IT, SC group, respectively. Renal outcomes were remarkably better in CS group(4.6%)compared with SC(14.4%)and IT(11.5%)group(p<0.001). Moreover, 36-month and 80-month renal survival was significantly better in CS group (98.3% and 86.4 %)than in the IT(94.2% and 82.4%)and SC(94.0% and 51.6%)group. Early CKD stage disease presented with better kidney survival(p<0.001). Further analysis for CKD stage 1 patients suggested no difference among 3 groups.In CKD stage 2 patients,CS alone or with IT could improve renal survival rate when compared with SC alone(p<0.001and 0.007). But,no statistical significant difference could be found between CS and IT groups(p=0.219). For CKD stage 3a patients,renal survival rate in 3 groups were poor(p=0.398). Multivariate model showed that hypertension(HR 1.99, 95% CI 1.16-3.42;p=0.012); serum creatinine (HR 1.02, 95%CI 1.00-1.05;p=0.024); E1 lesion(HR 3.10, 95% CI 1.14-8.42;P=0.027) and T1/T2 lesion (HR 3.34, 95% CI 1.98-6.33;P<0.001)remained as independent predictors of renal survival.


The use of corticosteroids in addition to ACEI/ARB significantly improve the short-term renal outcome in early-stage IgAN patients.